Patents by Inventor Robert Owen Hughes

Robert Owen Hughes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220242859
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and/or compositions that are useful in medicine, and particularly for treating neurodegeneration (e.g., for reducing axonal degeneration). In some embodiments, the present disclosure provides compounds having a structure as set forth in Formula (I).
    Type: Application
    Filed: June 5, 2020
    Publication date: August 4, 2022
    Inventors: Robert Owen HUGHES, Rajesh DEVRAJ, Todd BOSANAC, Richard Andrew JARJES-PIKE, Andrew BREARLEY, Jonathan BENTLEY
  • Publication number: 20220194933
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
    Type: Application
    Filed: June 6, 2019
    Publication date: June 23, 2022
    Inventors: Robert Owen Hughes, Rajesh Devraj, Todd Bosanac, Richard Andrew Jarjes-Pike, Andrew Simon Brearley, Jonathan Bentley
  • Patent number: 11358967
    Abstract: The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 14, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Delphine Collin, Johanna Csengery, Robert Owen Hughes, Michael Robert Turner, Lifen Wu
  • Publication number: 20220072019
    Abstract: The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.
    Type: Application
    Filed: October 18, 2019
    Publication date: March 10, 2022
    Inventors: Todd BOSANAC, Rajesh DEVRAJ, Thomas ENGBER, Robert Owen HUGHES, Raul Eduardo KRAUSS
  • Publication number: 20220056013
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 24, 2022
    Inventors: Todd BOSANAC, Andrew Simon BREARLEY, Rajesh DEVRAJ, Robert Owen HUGHES, Richard Andrew JARJES-PIKE, Shelley Anne PARROTT
  • Patent number: 11253503
    Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: February 22, 2022
    Assignees: Washington University, Disarm Therapeutics, Inc.
    Inventors: Jeffrey Milbrandt, Kow Essuman, Yo Sasaki, Aaron DiAntonio, Xianrong Mao, Rajesh Devraj, Raul Eduardo Krauss, Robert Owen Hughes
  • Publication number: 20220040164
    Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: Jeffrey MILBRANDT, Kow Essuman, Yo Sasaki, Aaron Diantonio, Xianrong Mao, Rajesh Devraj, Raul Eduardo Krauss, Robert Owen Hughes
  • Publication number: 20220008405
    Abstract: The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 13, 2022
    Inventors: Todd BOSANAC, Rajesh DEVRAJ, Thomas ENGBER, Robert Owen HUGHES, Raul Eduardo KRAUSS
  • Publication number: 20210261540
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Inventors: Robert Owen Hughes, Rajesh Devraj, Todd Bosanac, Richard Andrew Jarjes-Pike, Andrew Simon Brearley, Jonathan Bentley
  • Publication number: 20210261537
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARMI and/or treating and/or preventing axonal degeneration. Provided SARMI inhibitors reduce or inhibit binding of NAD+ by SARMI and SARMI inhibitors bind to SARMI within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARMI).
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Inventors: Robert Owen Hughes, Rajesh Devraj, Todd Bosanac, Richard Andrew Jarjes-Pike, Andrew Simon Brearley, Jonathan Bentley
  • Publication number: 20210171527
    Abstract: The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: January 18, 2017
    Publication date: June 10, 2021
    Inventors: Delphine COLLIN, Johanna CSENGERY, Robert Owen HUGHES, Michael Robert TURNER, Lifen WU
  • Patent number: 10954215
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: March 23, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Robert Owen Hughes, Xiang Li, Peter Allen Nemoto, Lana Louise Smith Keenan, Lifen Wu, Zhaoming Xiong
  • Publication number: 20210002251
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Applicant: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt
  • Patent number: 10815213
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 27, 2020
    Assignee: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt
  • Publication number: 20200129493
    Abstract: The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 30, 2020
    Applicants: Washington University, Disarm Therapeutics, Inc.
    Inventors: Jeffrey MILBRANDT, Kow ESSUMAN, Yo SASAKI, Aaron DIANTONIO, Xianrong MAO, Rajesh DEVRAJ, Raul Eduardo KRAUSS, Robert Owen HUGHES
  • Publication number: 20200071298
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also en-compasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: December 12, 2017
    Publication date: March 5, 2020
    Inventors: Robert Owen HUGHES, Xiang LI, Peter Allen NEMOTO, Lana Louise SMITH KEENAN, Lifen WU, Zhaoming XIONG
  • Patent number: 10450314
    Abstract: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: October 22, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steven Richard Brunette, Johanna Csengery, Robert Owen Hughes, Xiang Li, Robert Sibley, Michael Robert Turner, Zhaoming Xiong
  • Publication number: 20190202798
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases cases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Applicant: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt
  • Patent number: 10266513
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseeases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: April 23, 2019
    Assignee: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt
  • Publication number: 20190002465
    Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 3, 2019
    Inventors: Johanna BAKONYI, Steven Richard BRUNETTE, Delphine COLLIN, Robert Owen HUGHES, Xiang LI, Shuang LIANG, Robert SIBLEY, Michael Robert TURNER, Lifen WU, Qiang ZHANG